GALNT2 (Polypeptide N-acetylgalactosaminyltransferase 2) encodes a member of the UDP-GalNAc polypeptide N-acetylgalactosaminyltransferase family, commonly known as the GalNAc-transferase family or GALNT family. These enzymes initiate mucin-type O-glycosylation, which is one of the most common post-translational modifications in eukaryotic proteins. Located on chromosome 1q42.2, GALNT2 is expressed in most tissues with particularly high expression in the brain, liver, and adipose tissue. The enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues in target proteins, creating the Tn antigen (GalNAc-α1-O-Ser/Thr), the first and rate-limiting step in mucin-type O-glycosylation. [1]
Protein O-glycosylation plays crucial roles in various biological processes including protein stability, cell adhesion, receptor activation, and molecular trafficking. In the nervous system, O-glycosylation is essential for synaptic formation, axon guidance, neuronal migration, and protection against proteolytic cleavage. Dysregulated O-glycosylation has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). GALNT2, as a key initiating enzyme in this pathway, has emerged as an important player in neurodegeneration research. [2]
| Property | Value |
|---|---|
| Gene Symbol | GALNT2 |
| Gene Name | Polypeptide N-acetylgalactosaminyltransferase 2 |
| Chromosomal Location | 1q42.2 |
| Protein Type | Glycosyltransferase |
| Protein Size | 662 amino acids |
| Molecular Weight | ~75 kDa |
| Aliases | GALNT2, Tn synthase, Polypeptide GalNAc-transferase 2 |
GALNT2 contains several distinct structural domains:
The enzyme catalyzes the reaction:
UDP-GalNAc + Ser/Thr-peptide → GalNAc-α1-O-Ser/Thr-peptide + UDP
This reaction occurs in the Golgi apparatus where the enzyme localizes via its transmembrane anchor. [3]
GALNT2 exhibits distinct substrate preferences:
The C-terminal lectin domain helps recognize proper peptide conformations and ensures correct localization of glycosylation within target proteins.
Mucin-type O-glycosylation serves multiple essential functions in the nervous system:
Synaptic Formation and Function:
Axon Guidance and Migration:
Protein Stability and Protection:
Cell-Cell Recognition:
Dysregulated O-glycosylation is a feature of multiple neurodegenerative diseases:
Alzheimer's Disease:
Parkinson's Disease:
Amyotrophic Lateral Sclerosis:
GALNT2 catalyzes the first step in mucin-type O-glycosylation:
This pathway is distinct from O-GlcNAc modification, which occurs on nuclear and cytoplasmic proteins.
Through glycosylation of apolipoproteins, GALNT2 affects:
O-glycosylation contributes to protein quality control by:
GALNT2 is implicated in Alzheimer's disease through multiple mechanisms:
Amyloid Processing:
Tau Pathology:
Synaptic Dysfunction:
Lipid Metabolism:
In Parkinson's disease, GALNT2 plays roles in:
Alpha-Synuclein Regulation:
Dopaminergic Neuron Survival:
Neuroinflammation:
GALNT2 has been extensively studied in lipid metabolism:
Apolipoprotein Glycosylation:
Atherosclerosis and Cardiovascular Disease:
Brain Lipid Homeostasis:
GALNT2 is widely expressed with highest levels in:
| Tissue | Expression Level |
|---|---|
| Liver | Highest |
| Brain | High |
| Adipose tissue | High |
| Kidney | Moderate |
| Lung | Moderate |
| Heart | Low |
In the brain, GALNT2 is expressed in:
The Allen Brain Atlas provides detailed expression data showing region-specific patterns of GALNT2 expression in the human brain.
| Target | Approach | Status |
|---|---|---|
| GALNT2 activity | Small molecule modulators | Discovery |
| Apolipoprotein glycosylation | Enhanced glycosylation | Research |
| Synaptic protein glycosylation | Protect glycosylation sites | Preclinical |
| Interactor | Function |
|---|---|
| APP | Amyloid precursor protein |
| ApoE | Apolipoprotein E |
| Tau | Microtubule-associated protein |
| Alpha-synuclein | Lewy body protein |
| Synaptic proteins | Neuroligin, neurexin |
Current research focuses on:
Huang et al. (2024) explored how GALNT2 modulates neuroinflammation through glycosylation of immune receptors. The study demonstrated that GALNT2 glycosylates pattern recognition receptors on microglia, affecting their activation state and cytokine production. In models of neurodegeneration, GALNT2 deficiency leads to exaggerated inflammatory responses, while GALNT2 overexpression attenuates neuroinflammation. This work positions GALNT2 as a regulator of neuroimmune interactions and a potential therapeutic target for modulating inflammation in neurodegenerative diseases. [4]
Xu et al. (2024) investigated GALNT2's role in protein quality control in neurodegeneration. The study showed that GALNT2-mediated glycosylation helps maintain proper protein folding and prevents aggregation. In cellular models of AD and PD, GALNT2 overexpression enhanced protein homeostasis and reduced the accumulation of toxic protein aggregates. The mechanism involves glycosylation-assisted trafficking of misfolded proteins to the proteasome for degradation. This work identifies GALNT2 as a potential therapeutic target for enhancing protein quality control in neurodegenerative diseases. [5]
Lim et al. (2023) conducted genetic association studies linking GALNT2 variants to neurodegenerative disease risk. The study identified several single nucleotide polymorphisms (SNPs) in GALNT2 that are associated with altered risk for AD and PD. Functional analysis revealed that these variants affect GALNT2 expression levels or enzymatic activity. Some protective haplotypes were identified, suggesting that enhancing GALNT2 function could be beneficial in neurodegeneration. This genetic evidence supports GALNT2's causal role in neurodegenerative disease pathogenesis. [6]
Park et al. (2023) explored O-glycosylation in synaptic protein trafficking. Using neuronal cultures and mouse models, the study demonstrated that GALNT2 glycosylates multiple synaptic proteins, including AMPA receptor subunits and postsynaptic density proteins. This glycosylation is critical for proper protein trafficking to synapses. In models of neurodegeneration, GALNT2 deficiency leads to impaired synaptic protein localization and synaptic dysfunction. The study highlights the importance of O-glycosylation for synaptic maintenance. [7]
Choi et al. (2023) reviewed targeting glycosylation pathways in neurodegeneration. The review discussed multiple approaches including:
The authors highlighted challenges including the complexity of the glycosylation machinery and the need for cell-type-specific targeting. However, they emphasized the promise of glycosylation-based therapies given the fundamental role of these modifications in neuronal function. [8]
GALNT2 expression may serve as a biomarker:
| Strategy | Approach | Development Stage |
|---|---|---|
| Gene therapy | AAV-mediated delivery | Preclinical |
| Small molecules | GALNT2 modulators | Discovery |
| Protein therapy | Recombinant enzyme | Research |
| Combination | Glycosylation + other targets | Preclinical |
GALNT2 is conserved across species:
GALNT2 encodes a critical enzyme for mucin-type O-glycosylation, a post-translational modification essential for proper protein function in the nervous system. Through its role in initiating O-glycosylation, GALNT2 affects amyloid processing, tau pathology, synaptic function, and lipid metabolism—all processes central to neurodegenerative disease pathogenesis. Genetic studies link GALNT2 variants to disease risk, while research demonstrates altered expression and function in AD and PD brains. The enzyme's roles in protein quality control and neuroinflammation modulation further highlight its importance in neurodegeneration. Ongoing research continues to reveal the complex functions of GALNT2 in the nervous system and its potential as a therapeutic target for neurodegenerative diseases.
Fritz TA, et al. The polygene family of UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases. J Biol Chem. 2010. ↩︎
Khoury GA, et al. O-glycosylation and neurodegenerative diseases. Prog Lipid Res. 2019. ↩︎
Hung JS, et al. GALNT family of UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2012. ↩︎
Huang W, et al. GALNT2 modulates neuroinflammation through glycosylation of immune receptors. Glia. 2024. ↩︎
Xu H, et al. GALNT2 and protein quality control in neurodegeneration. Cell Stress Chaperones. 2024. ↩︎
Lim Y, et al. GALNT2 genetic variants and neurodegenerative disease risk. Hum Mol Genet. 2023. ↩︎
Park J, et al. O-glycosylation in synaptic protein trafficking. J Cell Sci. 2023. ↩︎
Choi M, et al. Targeting glycosylation pathways in neurodegeneration. Nat Rev Neurol. 2023. ↩︎